Literature DB >> 32407214

Reply to N. Fazio.

Eileen M O'Reilly1, Wungki Park1, David P Kelsen1.   

Abstract

Year:  2020        PMID: 32407214      PMCID: PMC7367549          DOI: 10.1200/JCO.20.00833

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.

Authors:  Marwan Ghosn; Fadi Farhat; Joseph Kattan; Fariha Younes; Walid Moukadem; Fadi Nasr; Georges Chahine
Journal:  Am J Clin Oncol       Date:  2007-02       Impact factor: 2.339

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?

Authors:  Nicola Fazio
Journal:  J Clin Oncol       Date:  2020-05-14       Impact factor: 44.544

4.  Oxaliplatin-induced damage of cellular DNA.

Authors:  J M Woynarowski; S Faivre; M C Herzig; B Arnett; W G Chapman; A V Trevino; E Raymond; S G Chaney; A Vaisman; M Varchenko; P E Juniewicz
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

5.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Authors:  Eileen M O'Reilly; Jonathan W Lee; Mark Zalupski; Marinela Capanu; Jennifer Park; Talia Golan; Esther Tahover; Maeve A Lowery; Joanne F Chou; Vaibhav Sahai; Robin Brenner; Hedy L Kindler; Kenneth H Yu; Alice Zervoudakis; Shreya Vemuri; Zsofia K Stadler; Richard K G Do; Neesha Dhani; Alice P Chen; David P Kelsen
Journal:  J Clin Oncol       Date:  2020-01-24       Impact factor: 44.544

6.  Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.

Authors:  Jonas Philipp Becker; Johanna Weiss; Dirk Theile
Journal:  Toxicol Lett       Date:  2013-11-23       Impact factor: 4.372

7.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

8.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Authors:  Andrew Tutt; Holly Tovey; Maggie Chon U Cheang; Sarah Kernaghan; Lucy Kilburn; Patrycja Gazinska; Julie Owen; Jacinta Abraham; Sophie Barrett; Peter Barrett-Lee; Robert Brown; Stephen Chan; Mitchell Dowsett; James M Flanagan; Lisa Fox; Anita Grigoriadis; Alexander Gutin; Catherine Harper-Wynne; Matthew Q Hatton; Katherine A Hoadley; Jyoti Parikh; Peter Parker; Charles M Perou; Rebecca Roylance; Vandna Shah; Adam Shaw; Ian E Smith; Kirsten M Timms; Andrew M Wardley; Gregory Wilson; Cheryl Gillett; Jerry S Lanchbury; Alan Ashworth; Nazneen Rahman; Mark Harries; Paul Ellis; Sarah E Pinder; Judith M Bliss
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

9.  BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

Authors:  I Lohse; A Borgida; P Cao; M Cheung; M Pintilie; T Bianco; S Holter; E Ibrahimov; R Kumareswaran; R G Bristow; M-S Tsao; S Gallinger; D W Hedley
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

  9 in total
  1 in total

1.  Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance.

Authors:  Joaquina Martínez-Galán; Isabel Rodriguez; Octavio Caba
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.